Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$26.77 USD
+0.04 (0.15%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $26.76 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
RPRX 26.77 +0.04(0.15%)
Will RPRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RPRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RPRX
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
RPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Other News for RPRX
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
7 Biotech Stocks to Buy on the Dip: June 2024
Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Dividend Champion, Contender, And Challenger Highlights: Week Of June 9
Buy Rating Affirmed for Royalty Pharma Amidst Positive Earnings Forecast and Strategic Growth Deals